5-ASA to sulfasalazine drug switch program in patients with ulcerative colitis.

CONCLUSIONS: A pharmacist-administered drug switch program in patients with UC was significantly more difficult than anticipated, with questionable achievement of cost savings. This experience suggests that future drug switches and studies should focus on patient preferences for drug switching, as this may have implications for switching from brand name to biosimilar drugs.
PMID: 30020742 [PubMed - in process]

Source: The American Journal of Managed Care - July 1, 2018 Category: Health Management Authors: Goldsmith JR, Waljee AK, George T, Brown A, Choe HM, Noureldin M, Bernstein SJ, Higgins PDR Tags: Am J Manag Care Source Type: research